相关实验视频
Updated: Jan 10, 2026

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.9K
解开陶的折叠:在阿尔茨海默氏症的发病过程中的结构动态
Sarita Montaño1, Nabil Itzi Luna-Viramontes2, Elvis Cuevas3
1Laboratorio de bioinformática y simulación Molecular, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Sinaloa, Sinaloa, Mexico.
Advances in protein chemistry and structural biology
|November 27, 2025
概括
阿尔茨海默病 (AD) 涉及tau蛋白病理,包括神经纤维状结 (NFTs). Glu391的陶断层是早期的AD生物标志物,可能通过高酸化来抵消.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 是最常见的痴呆症,在全球影响超过5500万,其中三分之二是女性.
- 阿尔茨海默病是一种渐进的神经退行性疾病,病理变化在临床症状出现前15-20年开始.
- 关键的病理特征包括神经纤维状结 (NFT) 和神经性斑块.
研究的目的:
- 描述神经纤维状结 (NFT) 和它们的组成.
- 专注于tau蛋白的病理性处理,特别是Glu391.1.的截断.
- 为了研究断作为阿尔茨海默病早期生物标志物的作用.
主要方法:
- 对非虚拟货币的组织病理分析.
- 检查tau蛋白的翻译后修饰,包括过酸化和截断.
- 审查现有报告,并提出新的证据.
主要成果:
- NFT是由tau蛋白的双螺旋丝组成的.
- 蛋白经历过多酸化和截断等修饰,导致构造变化.
- 在Glu391 (PHF核心) 的切断被确定为一个关键的病理事件和早期的AD生物标志物.
结论:
- 这项研究强调了Glu391的蛋白切断是AD的关键病理事件.
- 过酸化的蛋白可能会作为一种神经保护机制,对抗有毒的PHF核心.
- 对病理的进一步研究可能会产生早期诊断工具和阿尔茨海默病的治疗点.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils
6.3K
6.3K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764

